The Dental and Pharmaceutical Benefits Agency, TLV
Lars Jaatinen is an experienced web manager and digital project manager with a background in marketing and communications. Currently serving as a web manager at TLV since July 2011, Lars has previously held roles such as web manager and agile product owner at Transportstyrelsen, and has worked as a consultant focusing on marketing coordination and communications. Additional experience includes project and systems management at ITT Water & Wastewater, channel marketing at Lexmark, and e-business coordination at Lexmark Sweden, where expertise in content creation and web management was developed. Lars holds a Bachelor of Business Administration in Marketing and Communications from Stockholm University, obtained in 1996.
This person is not in any teams
The Dental and Pharmaceutical Benefits Agency, TLV
The Dental and Pharmaceutical Benefits Agency, TLV, is a central government agency whose remit is to determine whether a pharmaceutical product or dental care procedure shall be subsidized by the state. Our duty is to examine which medicines, medical devices and dental care treatments will be subsidised by society. We also contribute to quality service and accessibility of pharmacies. Our duty is to examine which medicines, medical devices and dental care treatments will be subsidised by society.In addition to examining new medicines, we also work systematically to evaluate the medicines included in the high-cost threshold to determine whether their reimbursement should be maintained or restricted. On the pharmacy market our remit is to create the conditions for quality service and accessibility at pharmacies. We do this partly through the generic substitution system, the retail margin for pharmacies and by monitoring the pharmacy market. Furthermore, we decide how much a medicine or a medical device in the high-cost threshold should cost. And, we determine what margin pharmacies should use when selling products, meaning the difference between the wholesale and retail prices. We determine the pricing for new dosage forms, strengths and packaging and examine whether they should be included in the high-cost threshold.